Get Started

Explore Drug Targets

Deep-dive research on validated and emerging therapeutic targets with competitive landscapes, clinical data, and deal activity.

Target Landscape

Showing 15 targets

KRAS G12C
Oncology
Approved Drug Exists
Market Leader Amgen (AMGN) - LumakrasApproved
Challenger Revolution (RVMD) - ElironrasibPhase 2
8+ companies pursuing

Amgen, Mirati approved. Next-gen focus on combos.

RAS(ON) Multi
Oncology
Race to First
Frontrunner Revolution (RVMD) - DaraxonrasibPhase 3
Fast Follower Mirati/BMS - MRTX1133Phase 1
4 companies pursuing

First multi-RAS inhibitor; BTD granted.

Menin-MLL
Oncology
Approved Drug Exists
Market Leader Syndax (SNDX) - RevuforjApproved
Challenger Kura (KURA) - ZiftomenibPhase 3
3 companies pursuing

First-in-class for KMT2A AML.

TIGIT
Oncology
Race to First
Frontrunner Arcus/Gilead (RCUS) - DomvanalimabPhase 3
Fast Follower Merck (MRK) - VibostolimabPhase 3
10+ companies pursuing

Crowded checkpoint. Fc design matters.

B7-H3
Oncology
Race to First
Frontrunner MacroGenics (MGNX) - Vobramitamab duoPhase 3
Fast Follower Multiple - ADCs, CAR-TPhase 2
23 assets in development

Highly expressed in solid tumors with limited normal tissue.

View Full Landscape →
TL1A
I&I
Race to First
Frontrunner Spyre (SYRE) - SPY002Phase 2
Fast Follower Prometheus - PRA023Phase 2
9 assets in development

Hot IBD target with anti-fibrotic potential.

View Full Landscape →
FcRn
I&I
Approved Drug Exists
Market Leader argenx (ARGX) - VYVGARTApproved
Challenger Immunovant (IMVT) - IMVT-1402Phase 3
5 companies pursuing

$4B+ market. MG, CIDP, ITP.

IL-4Ra / IL-13
I&I
Approved Drug Exists
Market Leader Regeneron (REGN) - DupixentApproved
Challenger Apogee (APGE) - APG777Phase 2
4 companies pursuing

$13B+ blockbuster. Q12W dosing goal.

KIT (mast cell)
I&I
Race to First
Frontrunner Celldex (CLDX) - BarzolvolimabPhase 3
Fast Follower Allakos - VariousPhase 2
3 companies pursuing

Mast cell depletion for urticaria.

GLP-1/GIP dual
Metabolic
Approved Drug Exists
Market Leader Eli Lilly (LLY) - MounjaroApproved
Challenger Viking (VKTX) - VK2735Phase 3
10+ companies pursuing

$50B+ market. Oral formulation key.

View Report
Aldosterone synth
Cardiovascular
Race to First
Frontrunner Mineralys (MLYS) - LorundrostatPhase 3
Fast Follower Alnylam (ALNY) - ZilebesiranPhase 3
3 companies pursuing

CYP11B2 for resistant HTN.

DMD gene therapy
Rare Disease
Approved Drug Exists
Market Leader Sarepta (SRPT) - ElevidysApproved
Challenger Solid Bio - SGT-003Phase 1/2
4 companies pursuing

First DMD gene therapy approved.

Hepcidin mimetic
Rare Disease
Race to First
Frontrunner Protagonist (PTGX) - RusfertideNDA Filed
Fast Follower Disc Med (IRON) - VariousPhase 2
2 companies pursuing

First-in-class for PV. Takeda partner.

Nav1.6 / SCN8A
Neuro
Early Stage
Frontrunner Praxis (PRAX) - RelutriginePhase 2/3
Fast Follower None significant-
1 company pursuing

BTD for SCN8A epilepsy. Low competition.

T-type Ca2+ channel
Neuro
Race to First
Frontrunner Praxis (PRAX) - UlixacaltamidePhase 3
Fast Follower None significant-
1 company pursuing

BTD for essential tremor.